EPS for Array BioPharma Inc. (ARRY) Expected At $-0.24

January 20, 2018 - By Peter Erickson

 EPS for Array BioPharma Inc. (ARRY) Expected At $ 0.24
Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.05, from 1.16 in 2017Q2. It improved, as 34 investors sold Array BioPharma Inc. shares while 43 reduced holdings. 41 funds opened positions while 52 raised stakes. 190.80 million shares or 15.63% more from 165.02 million shares in 2017Q2 were reported.
Pinnacle Associate reported 0.67% in Array BioPharma Inc. (NASDAQ:ARRY). Credit Suisse Ag has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 238,759 shares. Manufacturers Life Ins Com The stated it has 0% in Array BioPharma Inc. (NASDAQ:ARRY). Swiss Retail Bank has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Tower Research Ltd (Trc) stated it has 28,518 shares. Weiss Multi holds 172,500 shares. Ameriprise Financial Inc holds 0% or 123,826 shares in its portfolio. Commonwealth Equity Services owns 25,805 shares for 0% of their portfolio. Td Asset Mngmt Inc owns 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 83,949 shares. Massachusetts-based Numeric Llc has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). North Star Invest Mngmt reported 0.08% stake. Principal Financial Group Incorporated owns 444,967 shares. Ameritas Investment Prtnrs Inc invested in 15,148 shares or 0.01% of the stock. Ubs Asset Americas owns 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 774,061 shares. Great West Life Assurance Can holds 0% in Array BioPharma Inc. (NASDAQ:ARRY) or 17,700 shares.

Since September 29, 2017, it had 0 insider purchases, and 6 sales for $13.29 million activity. VAN LUNSEN GIL J sold 39,928 shares worth $493,510. The insider Haddock Jason sold 7,500 shares worth $102,975. 38,865 shares were sold by LEFKOFF KYLE, worth $478,428. 819,671 shares were sold by Squarer Ron, worth $8.90M on Saturday, December 16.

Analysts expect Array BioPharma Inc. (NASDAQ:ARRY) to report $-0.24 EPS on February, 8.They anticipate $0.10 EPS change or 71.43 % from last quarter’s $-0.14 EPS. After having $-0.22 EPS previously, Array BioPharma Inc.’s analysts see 9.09 % EPS growth. The stock increased 2.02% or $0.26 during the last trading session, reaching $13.14. About 2.22 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since January 20, 2017 and is uptrending. It has outperformed by 159.81% the S&P500.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Array BioPharma had 29 analyst reports since June 3, 2016 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Monday, September 26 report. The firm has “Outperform” rating by Leerink Swann given on Monday, September 26. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cowen & Co on Wednesday, August 9. On Wednesday, May 31 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cowen & Co on Tuesday, October 31. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. Cantor Fitzgerald maintained the shares of ARRY in report on Wednesday, August 9 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Tuesday, July 18 with “Buy”. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 30. As per Wednesday, November 29, the company rating was maintained by Piper Jaffray.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.59 billion. The company??s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Prnewswire.com, which released: “Lifshitz & Miller LLP Announces Investigation of Alteryx, Inc., Array …” on December 28, 2017. Nasdaq.com‘s article titled: “Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares” and published on December 20, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: